Rhythm Pharmaceuticals, Inc. (RYTM)
Health Care ยท Pharmaceutical Preparations
Rhythm Pharmaceuticals, Inc. (RYTM) is listed on Nasdaq, where its shares have traded since October 5, 2017. SentiSense covers Rhythm Pharmaceuticals, Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations. The company reports 414 employees, and its corporate website is www.rhythmtx.com.
About Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
Latest reported results
Rhythm Pharmaceuticals Inc. reported revenue of $71.3 million for Q2 FY2026, up 46.9% from the same period a year earlier.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 294 institutions reported holding RYTM, with 77.2 million shares worth $8.5 billion in aggregate. The largest reported holders were Vanguard, RA Capital Management, and BlackRock. Of the 5 largest reported holders, 1 added shares, 2 reduced their positions and 2 held their positions unchanged during the quarter.
More on RYTM
- RYTM sentiment: whether news and social coverage of Rhythm Pharmaceuticals, Inc. leans bullish or bearish, and the stories driving it.
- RYTM ownership: all 294 reporting institutions, plus insider and congressional trades.
- RYTM financials: revenue, net income, operating margin and free cash flow through Q2 FY2026.
Frequently asked questions
What does Rhythm Pharmaceuticals, Inc. do?
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases.
What sector is RYTM in?
SentiSense classifies Rhythm Pharmaceuticals, Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations.
Where does RYTM stock trade?
Rhythm Pharmaceuticals, Inc. (RYTM) is listed on Nasdaq, where its shares have traded since October 5, 2017.
How many institutions own RYTM?
294 institutions reported a position in RYTM in 13F filings for the quarter ended June 30, 2026, worth $8.5 billion in total.